• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    The Radoff-Sudbury Group Reiterates the Need to Elect Directors with Governance, Turnaround and Wellness Industry Experience to LifeVantage's Board of Directors

    11/1/23 6:00:00 PM ET
    $DSAQ
    $EGY
    $FTLF
    $LFVN
    Blank Checks
    Finance
    Oil & Gas Production
    Energy
    Get the next $DSAQ alert in real time by email

    Highlights Radoff-Sudbury Group Nominees Will Bring Differentiated Experience and Fresh Perspectives to the Board

    Notes Leading Independent Proxy Advisory Firms ISS and Glass Lewis Concluded that Boardroom Change is Warranted

    Urges Stockholders to Vote for Dayton Judd, Michael Lohner and Bradley L. Radoff on the BLUE Proxy Card Ahead of the November 6th Annual Meeting

    Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the "Radoff-Sudbury Group," "we" or our "Group"), represent the largest stockholder of LifeVantage Corporation (NASDAQ:LFVN) ("LifeVantage" or the "Company"), collectively owning approximately 12.8% of the Company's outstanding stock. Today, the Group issued the following letter to LifeVantage stockholders ahead of the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") on November 6, 2023:

    ***

    Fellow Stockholders,

    The Radoff-Sudbury Group represents the largest stockholder of LifeVantage, meaning our interests are squarely aligned with yours. We believe replacing certain long-tenured directors with stockholder-nominated directors who possess CEO-level transformation, wellness industry and corporate governance experience can help ignite a lasting turnaround following a decade of poor performance. Ahead of next week's Annual Meeting, we want to emphasize the opportunity you have to facilitate long-overdue change at LifeVantage by electing the right directors.

    While we attempted to engage privately with the Board of Directors (the "Board") on ideas for creating value and a settlement, we have been met with sustained resistance. The Company made clear it was not open to welcoming new perspectives to the Board until 2027, which we believe is indicative of the tight grip that Chairman Garry Mauro and other over-tenured directors have on LifeVantage. That is why we have invested a significant amount of our time and capital to nominate a minority slate of individuals with highly relevant skillsets to address the Company's most urgent needs.

    As detailed below, we are seeking to remove Chairman Mauro, Michael Beindorff and Darwin Lewis from the Board due to their excessively long tenures, track records of value destruction and lack of relevant experience. We are asking for your support to elect our three independent nominees, who are committed to putting LifeVantage stockholders' long-term interests first.

    Radoff-Sudbury Group Independent Nominee

    Targeted Incumbent LifeVantage Director

    The Case for Supporting Our Group's Independent Nominee

     

    Dayton Judd

     

    • Chairman and CEO of FitLife Brands, Inc. (NASDAQ:FTLF) ("FitLife")
    • Delivered 2,263% in total stockholder returns ("TSR") while CEO of FitLife1
    • Delivered 173% in TSR while serving as a director at RLJ Entertainment, Inc. (NASDAQ:RLJE)2
    • CEO-level turnaround experience
    • Experienced public company board member
    • Consumer wellness product experience
    • Public company financial expertise
    • Audit Chair experience

    Meaningful LifeVantage stockholder with strong track record of value creation

     

     

    Garry Mauro

     

    • 15-year LifeVantage director tenure
    • -58% LifeVantage TSR during tenure as Chair3
    • No prior C-suite experience
    • No prior public board experience
    • No wellness or direct selling experience
    • No capital allocation experience
    • No prior audit experience

    No meaningful stock ownership in LifeVantage and has overseen significant value destruction

     

     

    Experience & Track Record Comparison

     

    • Mr. Judd is an experienced public company CEO and director with a strong track record of value creation, who owns ~6% of LifeVantage stock.
    • Mr. Judd possesses valuable CEO-level turnaround experience, corporate governance and strategic planning acumen and wellness industry expertise, which would be immediately additive in the boardroom.
    • Mr. Mauro has served as Chairman of LifeVantage for 10 years and on the Board for over 15 years. He has failed to effectively oversee the Company and enabled the destruction of significant value over his tenure.
    • Both ISS and Glass Lewis have recommended for Mr. Judd, while ISS has recommended stockholders remove Mr. Mauro.

     

     

    Michael Lohner

     

    • President, CFO and director of Direct Selling Acquisition Corp. (NYSE:DSAQ)
    • Corporate finance and capital allocation expertise
    • C-suite executive
    • Experienced public company board member
    • Experienced investor

    Experienced executive with strong track record of value creation

     

     

    Michael Beindorff

     

    • ~12-year LifeVantage director tenure
    • -44% LifeVantage director tenure TSR4
    • No wellness or direct selling experience
    • No capital allocation experience
    • No prior public board experience
    • No prior audit experience

    No meaningful stock ownership in LifeVantage

     

     

    Experience & Track Record Comparison

     

    • Mr. Lohner has extensive experience as an investor and executive of companies in the direct selling industry, unlike Mr. Beindorff, who possesses no relevant experience.
    • We believe Mr. Lohner's industry experience would help support LifeVantage's go-forward strategy and address recent significant consultant and customer attrition.
    • Additionally, Mr. Lohner would bring valuable experience in the areas of corporate finance and capital allocation, which are necessary to correct course following the value destruction Mr. Beindorff has presided over for nearly 12 years.
    • Notably, Glass Lewis recommended stockholders remove Mr. Beindorff, pointing to his "predominantly misaligned experiences" and role in overseeing the destruction of value during his nearly 12-year tenure.

     

     

    Bradley L. Radoff

     

    • Experienced public company board member
    • Delivered 720% in TSR while serving as a director at Support.com, Inc. (NASDAQ:SPRT)5
    • Delivered 239% in TSR as a director of VAALCO Energy, Inc. (NYSE:EGY, LSE: EGY)))6
    • Consumer goods industry experience
    • Audit Chair experience
    • Successful private investor
    • Private and public engagements have delivered sizable returns for stockholders

    Meaningful LifeVantage stockholder with strong track record of value creation

     

     

    Darwin Lewis

     

    • 6.5-year LifeVantage director tenure
    • -19% LifeVantage director tenure TSR7
    • Former sales and operations executive
    • No wellness or direct selling experience
    • No capital allocation experience
    • No prior audit experience
    • No prior public board experience

    No meaningful stock ownership in LifeVantage

     

     

    Experience & Track Record Comparison

     

    • Mr. Radoff is an experienced investor and public company director with a strong track record of value creation, who owns 6.8% of LifeVantage stock.
    • Mr. Radoff's capital allocation expertise, public board and audit chair experience would be additive to the Board, compared to Mr. Lewis, who lacks prior audit and relevant financial experience – despite serving as LifeVantage's Audit Committee Chair.
    • We believe Mr. Radoff's valuable perspectives and skillsets can help improve the Company's approach to capital allocation to help enhance value for stockholders.

     

    We believe the choice is clear: voting the BLUE Proxy Card for the entire Radoff-Sudbury Group slate can help ensure the Board begins to act on behalf of all LifeVantage employees, consultants, stockholders and stakeholders.

    We sincerely appreciate the thoughtful conversations and feedback we have received from you in recent weeks. If you have any further questions for us or would like to speak directly with our nominees, please contact our proxy solicitor at [email protected].

    Sincerely,

    Bradley L. Radoff

     

    Dayton Judd

     

    Sudbury Capital Fund, LP

     

    ***

    VOTE "FOR" THE HIGHLY QUALIFIED RADOFF-SUDBURY NOMINEES ON THE BLUE PROXY CARD AHEAD OF LIFEVANTAGE'S UPCOMING ANNUAL MEETING ON NOVEMBER 6, 2023.

    ONLY YOUR LATEST DATED VOTE COUNTS. IF YOU VOTED FOR THE COMPANY'S NOMINEES PREVIOUSLY, A LATER DATED VOTE FOR THE RADOFF-SUDBURY NOMINEES WILL OVERRIDE YOUR PRIOR VOTING INSTRUCTIONS.

    IF YOU HAVE ANY QUESTIONS REGARDING HOW TO VOTE, PLEASE CALL SARATOGA PROXY CONSULTING AT (888) 368-0379 OR (212) 257-1311 OR BY EMAIL AT [email protected].

    PLEASE KNOW THAT BOTH YOUR INTERACTION WITH OUR PROXY SOLICITOR AND YOUR VOTING DECISION ARE COMPLETELY CONFIDENTIAL. SIMILARLY, IF YOUR LIFEVANTAGE SHARES ARE HELD WITH A BROKER, YOUR VOTING DECISION IS COMPLETELY CONFIDENTIAL.

    ***

    1 Source: Bloomberg. TSR calculated from February 18, 2018 through October 30, 2023.

    2 Source: Bloomberg. TSR calculated from May 15, 2015 through October 31, 2018.

    3 Source: Bloomberg. TSR calculated from November 13, 2013 through August 10, 2023.

    4 Source: Bloomberg. TSR calculated from January 10, 2012 through August 10, 2023.

    5 Source: Bloomberg. TSR calculated from June 28, 2016 through September 9, 2021.

    6 Source: Bloomberg. TSR calculated from June 25, 2020 through January 28, 2022.

    7 Source: Bloomberg. TSR calculated from February 16, 2017 through August 10, 2023.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231101942914/en/

    Get the next $DSAQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DSAQ
    $EGY
    $FTLF
    $LFVN

    CompanyDatePrice TargetRatingAnalyst
    FitLife Brands Inc.
    $FTLF
    3/17/2025$21.00Buy
    Lake Street
    Lifevantage Corporation
    $LFVN
    1/14/2025$35.00Buy
    Craig Hallum
    Lifevantage Corporation
    $LFVN
    12/19/2024$26.00Buy
    Lake Street
    FitLife Brands Inc.
    $FTLF
    9/3/2024$40.00Buy
    ROTH MKM
    VAALCO Energy Inc.
    $EGY
    3/1/2023Buy
    Stifel
    More analyst ratings

    $DSAQ
    $EGY
    $FTLF
    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF FINANCIAL OFFICER York Jakob

    4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

    9/8/25 10:19:11 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Aure Carl converted options into 33,678 shares and covered exercise/tax liability with 16,610 shares, increasing direct ownership by 12% to 161,330 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    9/3/25 9:48:47 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Sales Officer Cunningham Kristen converted options into 43,902 shares and covered exercise/tax liability with 21,801 shares, increasing direct ownership by 19% to 138,706 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    9/3/25 9:48:40 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSAQ
    $EGY
    $FTLF
    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewis Darwin bought $4,873 worth of shares (379 units at $12.86), increasing direct ownership by 0.33% to 116,767 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    6/17/25 4:11:27 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    5/13/25 4:11:14 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ordal Todd bought $3,621 worth of shares (300 units at $12.07), increasing direct ownership by 0.48% to 62,488 units (SEC Form 4)

    4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

    4/16/25 8:00:07 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $DSAQ
    $EGY
    $FTLF
    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025

    SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2025. Fourth Quarter Fiscal 2025 Summary*: Revenue of $55.1 million, an increase of 12.6% from the prior year period. Excluding the impact of foreign currency fluctuations, fourth quarter revenue increased approximately 11.6%;Revenue in the Americas increased 14.1% and revenue in Asia/Pacific & Europe increased 7.6%. Excluding foreign currency fluctuations, fourth quarter revenue in Asi

    9/4/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

    SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the H.C. Wainwright 27th Annual Global Investment Conference, to be held September 8-10, 2025 in New York, NY. Mr. Fife and Mr. Aure will meet with investors and present at approximately 1:00 p.m. Eastern Time on Wednesday, September 10, 2025. A live webcast of their presentation will be accessible on the News & Events section of the Company's Investor R

    9/2/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSAQ
    $EGY
    $FTLF
    $LFVN
    SEC Filings

    View All

    Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lifevantage Corp (0000849146) (Filer)

    9/4/25 4:06:47 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Lifevantage Corporation

    10-K - Lifevantage Corp (0000849146) (Filer)

    9/4/25 4:06:10 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FitLife Brands Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

    8/19/25 4:30:41 PM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $DSAQ
    $EGY
    $FTLF
    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on FitLife Brands with a new price target

    Lake Street initiated coverage of FitLife Brands with a rating of Buy and set a new price target of $21.00

    3/17/25 8:22:47 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on Lifevantage with a new price target

    Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

    1/14/25 8:36:52 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Lifevantage with a new price target

    Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

    12/19/24 8:39:43 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSAQ
    $EGY
    $FTLF
    $LFVN
    Leadership Updates

    Live Leadership Updates

    View All

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FitLife Brands Announces Board Transition

    Omaha, NE, April 28, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, announced today the resignation of Todd Ordal as a member of the Company's Board of Directors. Mr. Ordal's resignation, effective on April 25, 2025, was part of the Company's ongoing commitment to refresh board composition on a regular basis in accordance with good corporate governance practices and was not the result of any disagreement with the Company's management or the Board of Directors regarding any matter related to the Company or otherwise. On April 25, 2025, the Board of Directors of

    4/28/25 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

    SALT LAKE CITY, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is proud to announce the addition of Todd Thompson as Chief Information and Innovation Officer. Todd brings decades of experience driving transformative technology solutions and business growth for prominent global organizations. "We are thrilled to welcome Todd to the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "Todd's exceptional track record in technology leadership and his forward-thinking approach will be pivotal as we continue along our growth path

    1/16/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DSAQ
    $EGY
    $FTLF
    $LFVN
    Financials

    Live finance-specific insights

    View All

    $DSAQ
    $EGY
    $FTLF
    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025

    SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2025. Fourth Quarter Fiscal 2025 Summary*: Revenue of $55.1 million, an increase of 12.6% from the prior year period. Excluding the impact of foreign currency fluctuations, fourth quarter revenue increased approximately 11.6%;Revenue in the Americas increased 14.1% and revenue in Asia/Pacific & Europe increased 7.6%. Excluding foreign currency fluctuations, fourth quarter revenue in Asi

    9/4/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Aug. 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid September 16, 2025 to all stockholders of record at the close of business on September 8, 2025. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our pr

    8/28/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2025 Results on September 4, 2025

    SALT LAKE CITY, Aug. 21, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its fourth quarter and full fiscal year ended June 30, 2025, after the stock market closes on Thursday, September 4, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available appr

    8/21/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Direct Selling Acquisition Corp.

    SC 13G/A - Direct Selling Acquisition Corp. (0001871745) (Subject)

    11/14/24 1:29:57 PM ET
    $DSAQ
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Direct Selling Acquisition Corp.

    SC 13G/A - Direct Selling Acquisition Corp. (0001871745) (Subject)

    11/13/24 5:41:56 PM ET
    $DSAQ
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by VAALCO Energy Inc.

    SC 13G/A - VAALCO ENERGY INC /DE/ (0000894627) (Subject)

    11/12/24 5:48:11 PM ET
    $EGY
    Oil & Gas Production
    Energy